AstraZeneca PLC

AZN
Real-time CHI-X EUROPE LIMITED. - 02/20 11:30:00 am
7595GBp
-0.33%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2019 2020 (e)
Sales 24 384 26 842
EBITDA 6 686 8 268
Operating profit (EBIT) 6 436 7 449
Pre-Tax Profit (EBT) 1 548 3 773
Net income 1 335 3 013
P/E ratio 97,9x 39,9x
EPS ( $ ) 1,03 2,47
Dividend per Share ( $ ) 2,80 2,84
Yield 2,78% 2,88%
Reference price ( $ ) 100,869 98,424
Announcement Date 02/14/2020
07:01am
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2019 2020 (e)
Debt 12 009 13 388
Finance - -
Operating income (EBITDA) 6 686 8 268
Leverage
(Debt/EBITDA)
1,80x 1,62x
Capital Expenditure 979 1 157
Free Cash Flow (FCF) 1 990 4 223
Book Value Per Share (BVPS) ( $ ) 10,1 10,9
Cash Flow per Share ( $ ) 2,28 4,58
Announcement Date 02/14/2020
07:01am
-
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 129 151 M $ -
Entreprise Value (EV) 142 539 M $ 140 940 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) 39,9x 27,1x
Capitalization / Revenue 4,81x 4,34x
EV / Revenue 5,31x 4,79x
EV / EBITDA 17,2x 14,3x
Yield (DPS / Price) 2,88% 2,94%
Price to book (Price / BVPS) 9,02x 7,94x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 27,7% 30,9%
Operating Leverage (Delta EBIT / Delta Sales) 1,56x 2,14x
Net Margin (Net Profit / Revenue) 11,2% 16,7%
ROA (Net Profit / Asset) 5,20% 10,0%
ROE (Net Profit / Equities) 37,1% 44,1%
Rate of Dividend 115% 79,6%
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   4,31% 4,23%
Cash Flow / Sales 22,4% 25,4%
Capital Intensity (Assets / Sales) 2,16x 1,67x
Financial Leverage (Net Debt / EBITDA) 1,62x 1,18x
Price Earning Ratio
BNA & Dividende